On January 27, 2021, Narrow River Management announced the formation and completion of a Series A financing for two new companies—River 2 Renal Corp. (R2R) and River 3 Renal Corp (R3R). Leading the investment into the companies were SR One and Bain Capital Life Sciences. Wilson Sonsini Goodrich & Rosati advised SR One in the transaction.

In the transaction, each company raised a total of $40 million in Series A financing. The funds will support the development of novel therapies targeting orphan diseases in the renal space. Both companies will be managed by the Narrow River team.

R2R and R3R represent the second and third companies formed by Narrow River, the first of which was River Vision Development Corp. SR One, a leading trans-Atlantic biotech venture capital firm, was one of the lead investors in River Vision and had been working with Narrow River to identify and license promising molecules for development.

The Wilson Sonsini team advising SR One includes partners Dan Koeppen, Miranda Biven, and Michael Hostetler, and associates Lauren Wardle and Meghan Burton.

For more information, please see Narrow River’s press release.